vs
Side-by-side financial comparison of Currenc Group Inc. (CURR) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $10.1M, roughly 1.4× Currenc Group Inc.). FENNEC PHARMACEUTICALS INC. runs the higher net margin — -34.7% vs -46.5%, a 11.7% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs -23.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
CURR vs FENC — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.1M | $13.8M |
| Net Profit | $-4.7M | $-4.8M |
| Gross Margin | 31.8% | — |
| Operating Margin | -43.0% | -18.5% |
| Net Margin | -46.5% | -34.7% |
| Revenue YoY | -23.3% | 73.8% |
| Net Profit YoY | -54.0% | -141.1% |
| EPS (diluted) | $-0.13 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.8M | ||
| Q3 25 | — | $12.5M | ||
| Q2 25 | — | $9.7M | ||
| Q1 25 | $10.1M | $8.8M | ||
| Q4 24 | — | $7.9M | ||
| Q3 24 | $11.3M | $7.0M | ||
| Q2 24 | — | $7.3M | ||
| Q1 24 | $13.1M | $25.4M |
| Q4 25 | — | $-4.8M | ||
| Q3 25 | — | $-638.0K | ||
| Q2 25 | — | $-3.2M | ||
| Q1 25 | $-4.7M | $-1.2M | ||
| Q4 24 | — | $-2.0M | ||
| Q3 24 | $-5.0M | $-5.7M | ||
| Q2 24 | — | $-5.6M | ||
| Q1 24 | $-3.0M | $12.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 31.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 27.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 33.6% | — |
| Q4 25 | — | -18.5% | ||
| Q3 25 | — | -1.5% | ||
| Q2 25 | — | -28.3% | ||
| Q1 25 | -43.0% | -9.2% | ||
| Q4 24 | — | -11.8% | ||
| Q3 24 | -141.5% | -74.6% | ||
| Q2 24 | — | -69.4% | ||
| Q1 24 | -10.8% | 54.2% |
| Q4 25 | — | -34.7% | ||
| Q3 25 | — | -5.1% | ||
| Q2 25 | — | -32.7% | ||
| Q1 25 | -46.5% | -13.3% | ||
| Q4 24 | — | -25.0% | ||
| Q3 24 | -44.1% | -82.2% | ||
| Q2 24 | — | -76.5% | ||
| Q1 24 | -23.2% | 50.6% |
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | $-0.13 | $-0.04 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | $-0.13 | $-0.21 | ||
| Q2 24 | — | $-0.20 | ||
| Q1 24 | $-0.09 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $62.3M | $36.8M |
| Total DebtLower is stronger | $3.7M | — |
| Stockholders' EquityBook value | $-68.4M | $35.5M |
| Total Assets | $110.8M | $70.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $36.8M | ||
| Q3 25 | — | $21.9M | ||
| Q2 25 | — | $18.7M | ||
| Q1 25 | $62.3M | $22.7M | ||
| Q4 24 | — | $26.6M | ||
| Q3 24 | $49.1M | $40.3M | ||
| Q2 24 | — | $43.1M | ||
| Q1 24 | — | $51.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | $19.4M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | $3.7M | $19.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | $20.1M | $32.1M | ||
| Q2 24 | — | $31.8M | ||
| Q1 24 | — | $31.3M |
| Q4 25 | — | $35.5M | ||
| Q3 25 | — | $-4.5M | ||
| Q2 25 | — | $-7.5M | ||
| Q1 25 | $-68.4M | $-5.9M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | $-47.0M | $-5.2M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | $-10.9M | $3.0M |
| Q4 25 | — | $70.6M | ||
| Q3 25 | — | $49.3M | ||
| Q2 25 | — | $44.9M | ||
| Q1 25 | $110.8M | $46.4M | ||
| Q4 24 | — | $44.9M | ||
| Q3 24 | $115.0M | $58.9M | ||
| Q2 24 | — | $63.2M | ||
| Q1 24 | $54.5M | $69.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.5M | $-6.0M |
| Free Cash FlowOCF − Capex | $-1.7M | — |
| FCF MarginFCF / Revenue | -16.5% | — |
| Capex IntensityCapex / Revenue | 1.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-6.0M | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | — | $-3.7M | ||
| Q1 25 | $-1.5M | $-4.3M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | $-11.3M | $-2.2M | ||
| Q2 24 | — | $-8.4M | ||
| Q1 24 | $-221.0K | $39.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-233.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -16.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CURR
| Sales Of Airtime | $5.5M | 54% |
| Fiat Remittance Service | $4.4M | 44% |
FENC
Segment breakdown not available.
